Workflow
Grabar Law Office Investigates Claims on Behalf of Long-Term Shareholders of BioAge Labs, Inc. (NASDAQ: BIOA); NAPCO Security Technologies, Inc. (NASDAQ: NSSC); Treace Medical Concepts, Inc. (NASDAQ: TMCI); and Virtu Financial Inc. (NASDAQ: VIRT)
BIOABioage Labs, Inc.(BIOA) Newsfilter·2025-04-17 11:31

BioAge Labs, Inc. - BioAge Labs completed its IPO on September 27, 2024, selling 12.65 million shares at 18pershare,butthestockpricefellsignificantlyaftertheannouncementofdiscontinuingtheSTRIDESPhase2studyduetolivertransaminitisobservedinsubjects[2][4]−Followingthediscontinuationoftheclinicaltrial,BioAge′sstockpricedroppedfrom18 per share, but the stock price fell significantly after the announcement of discontinuing the STRIDES Phase 2 study due to liver transaminitis observed in subjects [2][4] - Following the discontinuation of the clinical trial, BioAge's stock price dropped from 20.09 on December 6, 2024, to 4.65onDecember7,2024[2]−AfederalsecuritiesfraudclassactioncomplaintwasfiledagainstBioAgeanditsofficers,allegingthattheymademateriallyfalseandmisleadingstatementsregardingtheSTRIDESPhase2clinicaltrialandfailedtodisclosesafetyconcerns[3][4]NAPCOSecurityTechnologies,Inc.−AsecuritiesfraudclassactioncomplaintagainstNAPCOhassurvivedamotiontodismiss,allegingthatthecompanymademateriallyfalsestatementsregardinginternalcontrolsandfinancialstatements[7][9]−ThecomplaintclaimsthatNAPCOoverstatedinventoryandnetcostofgoodssold,leadingtoinflatedgrossprofitandnecessitatingarestatementoffinancialstatements[8][9]−Thecourtfoundthatplaintiffsadequatelypledclaimsofwrongdoingbasedonunusualstocksalesbyofficers,whichtotaledover4.65 on December 7, 2024 [2] - A federal securities fraud class action complaint was filed against BioAge and its officers, alleging that they made materially false and misleading statements regarding the STRIDES Phase 2 clinical trial and failed to disclose safety concerns [3][4] NAPCO Security Technologies, Inc. - A securities fraud class action complaint against NAPCO has survived a motion to dismiss, alleging that the company made materially false statements regarding internal controls and financial statements [7][9] - The complaint claims that NAPCO overstated inventory and net cost of goods sold, leading to inflated gross profit and necessitating a restatement of financial statements [8][9] - The court found that plaintiffs adequately pled claims of wrongdoing based on unusual stock sales by officers, which totaled over 108 million [9] Treace Medical Concepts, Inc. - A securities class action complaint alleges that Treace Medical made false statements regarding its primary product, the Lapiplasty 3D Bunion Correction System, and failed to disclose competition impacts on demand [11] - The complaint indicates that Treace's revenue declined and the company needed to accelerate plans for an alternative product due to competitive pressures [11] Virtu Financial Inc. - A securities fraud class action complaint against Virtu Financial has survived a motion to dismiss, alleging that the company failed to disclose deficiencies in its information access policies [14][15] - The court determined that employees had inappropriate access to sensitive non-public information, which could lead to regulatory scrutiny [16]